Details for Patent: RE48825

Which drugs does patent RE48825 protect, and when does it expire?

Patent RE48825 protects CAPLYTA and is included in one NDA.

This patent has twenty-two patent family members in sixteen countries.

Summary for Patent: RE48825

Title:	4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms
Abstract:	The present invention relates to toluenesulfonic acid addition salt crystals of 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′: 4,5]pyrrolo[1,2,3 -de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone, and methods of using such crystals as 5-hydroxytryptamine 2 receptor agonists and antagonists in treating disorders of the central nervous system.
Inventor(s):	John Tomesch, Lawrence P. Wennogle
Assignee:	Intra Cellular Therapies Inc
Application Number:	US16/294,607
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent RE48825
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent RE48825

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-002	Apr 22, 2022		RX	Yes	No	RE48825			Y
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-003	Apr 22, 2022		RX	Yes	No	RE48825			Y
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-001	Dec 20, 2019		RX	Yes	Yes	RE48825		Y	Y

International Family Members for US Patent RE48825

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009223701
Canada	2716730
China	102046175
China	105237536
Denmark	2262505
European Patent Office	2262505